Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Global Smart Inhalers Market (2020 to 2025) - by Components, Product, Application, Distribution Channel, End-use and Geography


DUBLIN, April 20, 2021 /PRNewswire/ -- The "Global Smart Inhalers Market (2020-2025) by Components, Product, Application, Distribution Channel, End-Use, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Smart Inhalers Market is estimated to be USD 118.35 Mn in 2020 and is expected to reach USD 257.38 Mn by 2025, growing at a CAGR of 16.81%.

Market Dynamics

Key factors such as growth in respiratory disorders such as asthma and Chronic Obstructive Pulmonary Diseases (COPD) and growing acceptance towards digital healthcare equipment have driven the demand for the smart inhaler market. Similarly, the demand for real-time monitoring devices in the healthcare sector has additionally supported the growth of the market further.
However, the high cost of smart inhalers and the evident presence and utilization of manual inhalers poses to be a restraining factor to the growth of the market.

Market Segmentation

The Global Smart Inhalers Market is segmented further based on Components, Product, Application, Distribution Channel, End-Use, and Geography.

By Components, the market is classified as solutions and services. Amongst the two, the solutions segment is estimated to hold the highest market share.

By Product, the market is classified as inhalers and nebulizers. Amongst the two, the inhalers segment is estimated to hold the highest market share.

By Application, the market is classified as asthma and chronic obstructive pulmonary disease (COPD). Amongst the two, the asthma segment is estimated to hold the highest market share.

By Distribution Channel, the market is classified as hospital pharmacies, retail pharmacies, and online channels. Amongst all, hospital pharmacies are estimated to hold the highest market share.

By End Use, the market is classified as patients, R&D, and others. Amongst all, the patient segment is estimated to hold the highest market share.

By Geography, North America is projected to lead the market.

Recent Developments
1. AptarGroup, Inc has partnered with Sonmol for developing connected drug delivery devices, digital therapies, and services platform for respiratory and other diseases - 21st April 2020
2. Teva Pharmaceuticals has got its 3rd Digi inhaler approved known as the ArmonAir Digihaler monotherapy maintenance treatment. It is considered the first-gen medicine-only dispenser. - 11th March 2020

Company Profiles

Some of the companies covered in this report are Teva Pharmaceuticals Industries Ltd., Vectura Group plc, AstraZeneca plc, Propeller Health, Adherium Limited, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Cohero Health LLC, OPKO Health Inc., and Novartis AG, etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

Report Highlights:

Key Topics Covered:

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rising prevalence of respiratory-related disorders
4.2.1.2 Growth in real-time monitoring devices
4.2.1.3 Rising acceptance towards digital healthcare equipment
4.2.2 Restraints
4.2.2.1 High price of the smart inhalers
4.2.2.2 Presence of manual inhalers
4.2.3 Opportunities
4.2.3.1 Technological Advancements
4.2.3.2 Growing collaborations between smart inhaler manufacturers and software companies
4.2.4 Challenges
4.2.4.1 Limited product availability in emerging markets
4.3 Trends

5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6 Global Smart Inhalers Market, By Component
6.1 Introduction
6.2 Solutions
6.3 Services

7 Global Smart Inhalers Market, By Product
7.1 Introduction
7.2 Inhalers
7.2.1 Dry Powder Inhaler
7.2.2 Metered-Dose Inhaler
7.3 Nebulizer

8 Global Smart Inhalers Market, By Application
8.1 Introduction
8.2 Asthma
8.3 COPD

9 Global Smart Inhalers Market, By Distribution channel
9.1 Introduction
9.2 Hospitals Pharmacies
9.3 Retail Pharmacies
9.4 Online channel

10 Global Smart Inhalers Market, By End Use
10.1 Introduction
10.2 Patients
10.3 R&D
10.4 Others

11 Global Smart Inhalers Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 South America
11.3.1 Brazil
11.3.2 Argentina
11.4 Europe
11.4.1 UK
11.4.2 France
11.4.3 Germany
11.4.4 Italy
11.4.5 Spain
11.4.6 Rest of Europe
11.5 Asia-Pacific
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Indonesia
11.5.5 Malaysia
11.5.6 South Korea
11.5.7 Australia
11.5.8 Russia
11.5.9 Rest of APAC
11.6 Rest of the World
11.6.1 Qatar
11.6.2 Saudi Arabia
11.6.3 South Africa
11.6.4 United Arab Emirates
11.6.5 Latin America

12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Mergers & Acquisitions
12.3.2 Agreement, Collaborations, & Partnerships
12.3.3 New Product Launches & Enhancements
12.3.4 Investments & Funding

13 Company Profiles
13.1 OPKO Health, Inc.
13.2 AstraZeneca plc
13.3 GlaxoSmithKline
13.4 Propeller Health (ResMed Inc)
13.5 Aptar Pharma
13.6 Novartis AG
13.7 Boehringer Ingelheim
13.8 Teva Pharmaceuticals
13.9 H&T Presspart Manufacturing Ltd.
13.10 Sensirion AG
13.11 Cohero Health, Inc (AptarGroup Inc)
13.12 Adherium Limited
13.13 Gecko Health Innovations, Inc (Teva Pharmaceuticals)
13.14 Agilent Technologies
13.15 3M Medical
13.16 Inspiro Medical (OPKO Health Inc)
13.17 Findair Sp. z o. o.
13.18 Vectura Group
13.19 Zeolr Technologies Pvt Ltd.
13.20 ResMed, Inc.

14 Appendix
14.1 Questionnaire

For more information about this report visit https://www.researchandmarkets.com/r/c0fw0r

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....



News published on and distributed by: